MX376532B - Derivado de dihidropiridazin-3,5-diona. - Google Patents

Derivado de dihidropiridazin-3,5-diona.

Info

Publication number
MX376532B
MX376532B MX2015012537A MX2015012537A MX376532B MX 376532 B MX376532 B MX 376532B MX 2015012537 A MX2015012537 A MX 2015012537A MX 2015012537 A MX2015012537 A MX 2015012537A MX 376532 B MX376532 B MX 376532B
Authority
MX
Mexico
Prior art keywords
dihydropyridazine
dione derivative
prophylactic
salt
derivative
Prior art date
Application number
MX2015012537A
Other languages
English (en)
Spanish (es)
Other versions
MX2015012537A (es
Inventor
Takeo Harada
Nobuyuki Hori
Naoshi Horiba
Hirotaka Kashiwagi
Yasuhiro Ichida
Mitsuaki Ide
Atsushi Kimbara
Eisaku Mizuguchi
Yoshihisa Murata
Kenichi Nomura
Yoshihito Ohtake
Shuichi Ohtomo
Naoki Okamoto
Yoshiyuki Ono
Kazutaka Tachibana
Shota Tanaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2015012537A publication Critical patent/MX2015012537A/es
Publication of MX376532B publication Critical patent/MX376532B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/504Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
MX2015012537A 2013-03-13 2014-03-13 Derivado de dihidropiridazin-3,5-diona. MX376532B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013132889 2013-06-25
PCT/JP2014/056778 WO2014142273A1 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン-3,5-ジオン誘導体

Publications (2)

Publication Number Publication Date
MX2015012537A MX2015012537A (es) 2016-02-10
MX376532B true MX376532B (es) 2025-03-07

Family

ID=51536921

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012537A MX376532B (es) 2013-03-13 2014-03-13 Derivado de dihidropiridazin-3,5-diona.

Country Status (29)

Country Link
EP (2) EP2975030B1 (https=)
JP (2) JP5814488B2 (https=)
KR (2) KR102072268B1 (https=)
CN (1) CN105073715B (https=)
AU (1) AU2014230552B2 (https=)
BR (1) BR112015022092B1 (https=)
CA (1) CA2901868C (https=)
CL (1) CL2015002543A1 (https=)
CR (1) CR20150505A (https=)
DK (1) DK2975030T3 (https=)
ES (1) ES2811126T3 (https=)
HR (1) HRP20201211T1 (https=)
HU (1) HUE050577T2 (https=)
IL (1) IL240825B (https=)
LT (1) LT2975030T (https=)
MX (1) MX376532B (https=)
MY (1) MY174269A (https=)
NZ (1) NZ711182A (https=)
PE (1) PE20151535A1 (https=)
PH (1) PH12015501940B1 (https=)
PL (1) PL2975030T3 (https=)
PT (1) PT2975030T (https=)
RS (1) RS60911B1 (https=)
RU (1) RU2662832C2 (https=)
SG (1) SG11201507345RA (https=)
SI (1) SI2975030T1 (https=)
TW (2) TWI683811B (https=)
UA (1) UA118755C2 (https=)
WO (1) WO2014142273A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2975030T (pt) * 2013-03-13 2020-09-28 Chugai Pharmaceutical Co Ltd Derivado de di-hidropiridazina-3,5-diona
NZ729640A (en) * 2014-09-12 2022-04-29 Chugai Pharmaceutical Co Ltd Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料(常州)有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
KR20230033708A (ko) * 2020-06-26 2023-03-08 니혼노야쿠가부시키가이샤 아릴테트라히드로피리다진 유도체 또는 그의 염류 및 해당 화합물을 함유하는 살충제 그리고 그 사용 방법
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
KR20240018523A (ko) 2021-06-08 2024-02-13 추가이 세이야쿠 가부시키가이샤 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제
CA3244263A1 (en) 2021-12-28 2025-06-13 Nihon Nohyaku Co., Ltd. ARYL TETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, PESTICIDE CONTAINING SAID COMPOUND AND ASSOCIATED METHOD OF USE
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2292337C2 (ru) * 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
SG177981A1 (en) * 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2008053043A1 (de) * 2006-11-03 2008-05-08 Basf Se Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
EP2334682B1 (en) * 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
PL2565190T3 (pl) 2010-04-28 2015-10-30 Astellas Pharma Inc Związek tetrahydrobenzotiofenowy
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827327B2 (ja) * 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
ES2585415T3 (es) 2011-10-27 2016-10-05 Astellas Pharma Inc. Derivado de N-tienilbenzamida sustituida con aminoalquilo
PT2975030T (pt) * 2013-03-13 2020-09-28 Chugai Pharmaceutical Co Ltd Derivado de di-hidropiridazina-3,5-diona

Also Published As

Publication number Publication date
BR112015022092A2 (pt) 2017-07-18
LT2975030T (lt) 2020-09-25
TWI683811B (zh) 2020-02-01
EP2975030A1 (en) 2016-01-20
HK1212700A1 (zh) 2016-06-17
WO2014142273A1 (ja) 2014-09-18
CR20150505A (es) 2015-10-26
RU2662832C2 (ru) 2018-07-31
UA118755C2 (uk) 2019-03-11
SG11201507345RA (en) 2015-10-29
CL2015002543A1 (es) 2016-02-26
AU2014230552B2 (en) 2017-11-16
IL240825A0 (en) 2015-10-29
CN105073715B (zh) 2017-12-01
CN105073715A (zh) 2015-11-18
SI2975030T1 (sl) 2020-10-30
JP2016040262A (ja) 2016-03-24
EP3757093A1 (en) 2020-12-30
HRP20201211T1 (hr) 2020-11-13
ES2811126T3 (es) 2021-03-10
EP2975030B1 (en) 2020-07-15
PL2975030T3 (pl) 2021-01-11
KR102072268B1 (ko) 2020-01-31
JPWO2014142273A1 (ja) 2017-02-16
CA2901868C (en) 2022-05-03
NZ711182A (en) 2020-05-29
MY174269A (en) 2020-04-01
PH12015501940A1 (en) 2016-01-11
TW201741304A (zh) 2017-12-01
PH12015501940B1 (en) 2016-01-11
CA2901868A1 (en) 2014-09-18
IL240825B (en) 2020-07-30
TWI596095B (zh) 2017-08-21
DK2975030T3 (da) 2020-08-31
JP5814488B2 (ja) 2015-11-17
RU2015143507A (ru) 2017-04-19
AU2014230552A1 (en) 2015-08-13
KR20160119282A (ko) 2016-10-12
TW201446756A (zh) 2014-12-16
PE20151535A1 (es) 2015-10-28
RS60911B1 (sr) 2020-11-30
PT2975030T (pt) 2020-09-28
MX2015012537A (es) 2016-02-10
JP6420738B2 (ja) 2018-11-07
HUE050577T2 (hu) 2020-12-28
KR101664460B1 (ko) 2016-10-10
EP2975030A4 (en) 2016-08-03
BR112015022092A8 (pt) 2018-01-23
KR20150127721A (ko) 2015-11-17
BR112015022092B1 (pt) 2023-04-11

Similar Documents

Publication Publication Date Title
PH12015501940B1 (en) Dihydropyridazine-3,5-dione derivative
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MY197700A (en) Compounds useful for inhibiting cdk7
PH12016500756A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX356536B (es) Compuesto inhibidor de la señalización de la trayectoria notch.
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX383940B (es) Formulación farmacéutica que contiene tocol fosfato.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
MA38491A1 (fr) Dérivé dihydropyridazine-3,5-dione
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration